novo nordisk semaglutide oral oral glp-1 Nordisk's drug didn't work on Alzheimer's as hoped, but don't call it a failure FDA Approves Oral Semaglutide: First – Novo Nordisk wins EU approval

It plays a key role in converting fat into energy, making it useful for helping boost metabolism and supporting weight management

Early detection helps prevent complications like malnutrition, dehydration, and electrolyte imbalances

Adverse events In the STEP-1 trial, the rate of GI adverse events was 1.5 times higher in the semaglutide group vs

PMID: 35172807, PMCID: PMC8848673, DOI: 10.1186/s12889-022-12688-x

Monthly treatments deliver the best cumulative results for most clients

The industry is scrambling to outsmart these drugsdeveloping: - Hyper-palatable snacks that trigger cravings even on Ozempic - Healthier ultra-processed foods targeted at GLP-1 users - Fortified junk disguised as nutritious options Our food system is broken